Promotional investment grows Diovan and Zelnorm brands, Novartis marketing chief says

Share this article:
An investment in promotional strategy has helped fuel new prescription growth for Novartis brands Diovan and Zelnorm, chief marketing officer Kurt Graves said yesterday during UBS’ Global Life Sciences conference in New York. Graves highlighted Diovan’s “BP Success Zone” campaign, along with DTC advertising for Zelnorm, as marketing efforts that have helped Novartis boost its bottom line in recent months. “BP Success Zone has helped complement Diovan…growing sales 38.2% in June…And as a result of DTC investment, prescriptions for Zelnorm have been growing by over 30%,” Graves said. Novartis works with MicroMass Communications on its BP Success Zone efforts and Deutsche for its Zelnorm DTC ads. Meanwhile, Novartis remains optimistic about launches for a slew of pipeline products in the months ahead, with a sharp focus on Galvus (type 2 diabetes) and Exforge (hypertension). Detailing efforts for the new drugs will be category dependent, pending approval, Graves said. “What we don’t want to tell you is how we have set up our field force,” he added. “Every pharma company needs to come up with innovative go-to market strategies,” if it wants to be successful. Nancy Lurker, Novartis’ recently appointed SVP, chief marketing officer, said during a conference breakout session, that the scope of Novartis’ marketing efforts will undergo some changes in light of these anticipated new product launches. “You don’t see it growing; however, the channels are broadening,” she said.
Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.